Stammdaten
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Unternehmen & Branche
| Name | IO Biotech, Inc. |
|---|---|
| Ticker | IOBT |
| CIK | 0001865494 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 885.690 USD |
| Beta | 0,89 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | -8,378,000 | -0.13 | 39,956,000 | 911,000 | |
| 2025-06-30 | 10-Q | -26,217,000 | -0.40 | 42,326,000 | 1,592,000 | |
| 2025-03-31 | 10-Q | -22,421,000 | -0.34 | 45,736,000 | 26,422,000 | |
| 2024-12-31 | 10-Q | -95,500,000 | 67,699,000 | 47,015,000 | ||
| 2024-12-31 | 10-K | -95,491,000 | -1.45 | 67,699,000 | 47,015,000 | |
| 2024-09-30 | 10-Q | -24,015,000 | -0.36 | 89,945,000 | 72,565,000 | |
| 2024-06-30 | 10-Q | -20,686,000 | -0.31 | 111,467,000 | 96,272,000 | |
| 2024-03-31 | 10-Q | -19,457,000 | -0.30 | 128,159,000 | 115,466,000 | |
| 2023-12-31 | 10-K | -86,083,000 | -1.98 | 150,718,000 | 133,162,000 | |
| 2023-12-31 | 10-Q | -86,100,000 | 150,718,000 | 133,162,000 | ||
| 2023-09-30 | 10-Q | -21,679,000 | -0.43 | 172,553,000 | 157,592,000 | |
| 2023-06-30 | 10-Q | -21,178,000 | -0.74 | 117,555,000 | 104,520,000 | |
| 2023-03-31 | 10-Q | -17,044,000 | -0.59 | 136,844,000 | 124,215,000 | |
| 2022-12-31 | 10-Q | -71,500,000 | 151,805,000 | 138,854,000 | ||
| 2022-12-31 | 10-K | -71,458,000 | -2.48 | 151,805,000 | 138,854,000 | |
| 2022-09-30 | 10-Q | -15,688,000 | -0.54 | 162,157,000 | 153,489,000 | |
| 2022-06-30 | 10-Q | -18,495,000 | -0.64 | 182,645,000 | 172,177,000 | |
| 2022-03-31 | 10-Q | -17,204,000 | -0.60 | 202,171,000 | 193,693,000 | |
| 2021-12-31 | 10-Q | -67,900,000 | 222,288,000 | 211,924,000 | ||
| 2021-12-31 | 10-K | -67,879,000 | -17.30 | 222,288,000 | 211,924,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-05-30 | Hunter Heidi | Director | Open Market Purchase | 15,000 | 1.39 | 20,884.50 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.